Ali Mohammad Daud, Almadan Leena Zakariya, Alghamdi Ruba Ahmed, Alghamdi Alanood Saleh, Almarhoon Sarah Ali, Hassan Yousif A M, Ahmad Ayaz, Ghosn Sherihan Ahmad, Banu Nuzhat, Eltrafi Zainab
Department of Pharmacy, Mohammed Al-Mana College for Medical Sciences, Dammam, 34222, Saudi Arabia.
Infect Drug Resist. 2022 Aug 9;15:4335-4346. doi: 10.2147/IDR.S374265. eCollection 2022.
The purpose of this study was to examine the mild and moderate side-effects experienced by the healthcare workers (HCWs) in the Eastern Province of Saudi Arabia after receiving the booster dose of the Pfizer-BioNTech/BNT162b2 COVID-19 vaccine.
We directed a descriptive cross-sectional study among adults living in the Eastern Province of Saudi Arabia. A survey link was distributed through WhatsApp, SMS, or e-mail to HCWs. Participants' general and demographic information were also collected, as well as information about any local and systemic side-effects reported following vaccination.
The results of this study showed that 81.84% (401/490) of the HCWs who contributed to this study reported the minimum COVID-19 post-vaccination side-effect. Body pain (89%) and pain at the site of injection (88.73%) were the most frequent frequently reported side-effects, followed by headache (28.68%), joint or bone pain (27.18%), muscle pain (26.43%), nausea or vomiting (21.2%), fever (18.95%), skin rashes (10.22%). History of chronic diseases had a 0.44-fold increased risk of side-effects compared to no history of chronic diseases HCWs (adjusted odds ratio (aOR) = 0.44; 95% CI = 0.224, 0.880), and significant association of occupation with side-effects was also 1.61-fold increased risk compared to nonmedical ((aOR) = 1.61; 95% CI = 1.037, 2.513).
According to this study, the Pfizer-BioNTech/BNT162b2 COVID-19 vaccine was safe when given to Saudi Arabian HCWs. All reported side-effects were mild to moderate. The outcomes indicated that most participants had body pain and pain at the site of injection and fatigue is among the least reported side-effect post-booster dose. Healthcare was highly connected with more reporting of side-effects.
本研究旨在调查沙特阿拉伯东部省份的医护人员接种辉瑞 - 生物科技公司/BioNTech BNT162b2新冠疫苗加强针后出现的轻度和中度副作用。
我们对居住在沙特阿拉伯东部省份的成年人进行了一项描述性横断面研究。通过WhatsApp、短信或电子邮件向医护人员分发了调查链接。还收集了参与者的一般和人口统计学信息，以及接种疫苗后报告的任何局部和全身副作用的信息。
本研究结果显示，参与本研究的医护人员中有81.84%（401/490）报告了接种新冠疫苗后出现的最小副作用。身体疼痛（89%）和注射部位疼痛（88.73%）是最常报告的副作用，其次是头痛（28.68%）、关节或骨痛（27.18%）、肌肉疼痛（26.43%）、恶心或呕吐（21.2%）、发烧（18.95%）、皮疹（10.22%）。与无慢性疾病史的医护人员相比，有慢性疾病史的医护人员出现副作用的风险增加了0.44倍（调整后的优势比（aOR）=0.44；95%置信区间=0.224，0.880），职业与副作用之间也存在显著关联，与非医疗人员相比，出现副作用的风险增加了1.61倍（aOR = 1.61；95%置信区间=1.037，2.513）。
根据本研究，辉瑞 - 生物科技公司/BioNTech BNT162b2新冠疫苗在给沙特阿拉伯医护人员接种时是安全的。所有报告的副作用均为轻度至中度。结果表明，大多数参与者有身体疼痛和注射部位疼痛，疲劳是加强针后报告最少的副作用之一。医疗保健行业与更多的副作用报告高度相关。
